FMC Corporation 10-Q Summary: Quarter Ended September 30, 2025
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 30, 2025, and the nine months ended September 30, 2025. FMC Corporation is a global agricultural sciences company operating in a single segment, developing crop protection chemicals (insecticides, herbicides, fungicides) and plant health products. The reporting period is significantly impacted by the decision to divest the Company's commercial business in India, which was classified as "held for sale" beginning in the third quarter of 2025.
Key Financial Metrics
| Metric | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Revenue | $542.2M | $1,065.4M | $2,384.1M | $3,021.8M |
| Gross Margin | $128.9M (24%) | $386.4M (36%) | $851.9M (36%) | $1,124.2M (37%) |
| Net Income (Loss) Attributable to FMC | $(569.3M) | $65.0M | $(518.1M) | $357.4M |
| Diluted EPS | $(4.52) | $0.52 | $(4.11) | $2.85 |
| Operating Cash Flow (Continuing Ops) | N/A | N/A | $(663.3M) | $308.8M |
| Free Cash Flow (Non-GAAP) | N/A | N/A | $(788.5M) | $224.7M |
| Total Debt | $4,542.2M | N/A | N/A | N/A |
| Cash and Cash Equivalents | $497.7M | N/A | N/A | N/A |
Note: Q3 2025 Operating Cash Flow is not explicitly broken out in the provided text, only the 9-month figure is available.
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased 49% in Q3 2025 and 21% in the first nine months of 2025 compared to the prior year. This is primarily driven by one-time commercial actions totaling $419 million in revenue charges related to the India business divestiture. Excluding India, revenue decreased 10% in Q3 and 7% in the 9-month period due to pricing pressure and foreign currency headwinds.
- Net Loss: The Company reported a net loss of $569.3 million in Q3 2025, a reversal from a net income of $65.0 million in Q3 2024. The loss is driven by approximately $510 million in charges related to the India business (including $282.2 million in commercial adjustments and $226.8 million in asset impairment) and restructuring charges under "Project Focus."
- Restructuring Charges: Restructuring and other charges increased significantly to $294.5 million in Q3 2025 from $22.6 million in Q3 2024. This includes $49.9 million for Project Focus and $244.6 million in other charges, predominantly the India impairment.
- Debt Profile: Total debt increased to $4,542.2 million as of September 30, 2025, from $3,365.3 million at year-end 2024. This increase reflects the issuance of $750 million in Subordinated Notes in May 2025 and higher commercial paper balances, partially offset by the redemption of $500 million in senior notes.
Guidance, Outlook, and Management Commentary
- 2025 Outlook Update:
- Revenue (Excluding India): Expected to be $3.92 billion to $4.02 billion, down 7% at the midpoint versus 2024.
- Adjusted EBITDA: Expected to be $830 million to $870 million, down 6% at the midpoint versus 2024.
- Adjusted EPS: Expected to be $2.92 to $3.14 per diluted share, down 13% at the midpoint versus 2024.
- Free Cash Flow: Expected to range from negative $200 million to zero for the full year 2025.
- Dividend Reduction: The Board of Directors reduced the quarterly dividend to $0.08 per share, effective with the declaration in December 2025, to prioritize debt reduction.
- Share Repurchases: The Company suspended share repurchases under its publicly announced program until December 31, 2027, per credit agreement amendments. $825 million remains available under the program.
- India Divestiture: The sale process for the India commercial business is underway and expected to conclude within 12 months. The business is held for sale at a net asset value of $450 million.
- Project Focus: The Company expects total pre-tax restructuring charges for this initiative to range from $425 million to $475 million, with the plan expected to be complete by the end of 2025.
Investor Verification Checklist
- India Divestiture Timeline: Verify the progress of the sale process and the final valuation of the India business, as the $510 million charge significantly impacts current earnings.
- Working Capital Normalization: Monitor the normalization of working capital in 2025, which is expected to negatively impact free cash flow compared to the destocking environment of 2024.
- Debt Covenant Compliance: Confirm continued compliance with leverage and interest coverage covenants, noting the temporary relief granted in February 2025 (max leverage 5.25x through Q3 2025).
- Pricing Pressure: Assess the impact of generic competition and "cost-plus" contract adjustments on future pricing, which is expected to decline in the mid-to-high single digits.
- Environmental Liabilities: Review the $599.2 million in total environmental reserves and the projected $75 million to $95 million in spending for 2025.